New-onset ulcerative colitis in a patient treated with the anti-CD11a monoclonal antibody efalizumab.
Donnellan
Fergal
F
Cullen
Garret
G
Murray
Frank E
FE
D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003113:Colonoscopy; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007275:Injections, Intravenous; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage; D011860:Radiography, Abdominal; D012008:Recurrence
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D005938:Glucocorticoids; D019804:Mesalamine; D006854:Hydrocortisone; C472181:efalizumab